A cannabinoid is a compound that acts on cannabinoid receptors — primarily CB1 and CB2, two G protein-coupled receptors expressed throughout the nervous system and the immune system.[1] The class is defined pharmacologically: membership rests on receptor activity rather than on any single chemical scaffold or natural origin. By that definition, cannabinoids span three sources — plant compounds from Cannabis, endogenous lipid signals made by the body, and engineered laboratory compounds.
This class collects the phytocannabinoids from Cannabis — THC, CBD, and minor compounds such as CBG, CBC, CBN, and THCV — together with newer extended-chain homologs (THCP, THCH, THCB) and semi-synthetic derivatives such as HHC. Members differ widely in chemical structure and in how strongly they activate either receptor, yet they all converge on the same cannabinoid receptor system.
At low and moderate exposures, cannabinoid-active members produce relaxation, altered sensory perception, increased appetite, and a sense of ease, alongside mild cognitive slowing and impaired motor coordination. The class spans everyday recreational use of Cannabis, medical use for nausea, chronic pain, and seizure disorders, and a growing market in concentrates and novel homologs. At higher exposures, or with high-affinity members, anxiety, panic, and transient psychotic episodes become more likely.[2]
Pharmacology
Most members of this class converge on a single receptor system. CB1 and CB2 are G protein-coupled receptors that signal through Gi/o proteins, and their activation triggers a shared cascade: inhibition of adenylyl cyclase and reduced cyclic AMP, opening of inwardly rectifying potassium channels, closing of voltage-gated calcium channels, and modulation of MAPK signaling.[1]
CB1 sits primarily on presynaptic terminals throughout the brain — densely in prefrontal cortex, hippocampus, basal ganglia, cerebellum, and amygdala — and mediates the psychoactive, cognitive, and motor effects of the class. CB2 sits mainly in immune tissues and peripheral organs, where it modulates inflammatory signaling. The defining synaptic role is retrograde: endocannabinoids made on demand by postsynaptic neurons travel backward to presynaptic CB1, suppressing release of neurotransmitter across both excitatory and inhibitory synapses.[1]
| Receptor profile | Representative members | How it engages the shared system |
|---|---|---|
| CB1 partial agonism (psychoactive core) | THC, Δ-8-THC, Δ-10-THC, HHC | Activates CB1 with moderate efficacy; alkyl side-chain length tunes binding affinity[3] |
| High-affinity CB1 partial agonism | THCP, THCH | Same CB1 agonist mechanism but with markedly higher binding affinity from extended alkyl chains[3] |
| Low-affinity CB1/CB2 modulator | CBD | Binds CB1 only weakly; functionally antagonizes CB1 agonist activity; engages TRP channels, GPR55, and 5-HT1A[4] |
| Dose-dependent inversion | THCV | CB1 antagonist at low exposure; partial CB1 agonist at higher exposure; also a CB2 partial agonist[4] |
| CB2-selective | CBC | Activates CB2 with little CB1 agonism; its hyperpolarizing effect is blocked by CB2 antagonists[5] |
| Mixed minor agonist/antagonist | CBG, CBN | Partial agonism at both receptors with low potency, plus additional non-cannabinoid targets[6] |
The mechanistic detail matters less for the class identity than the convergent endpoint. Whatever the route — full or partial CB1 agonism, CB2 selectivity, or low-affinity modulation — every member shapes its profile by acting on the same receptor system, and the psychoactive intensity of any member tracks how strongly it activates CB1.[7]
Substances
The members span chemical structure and pharmacology, but a small set of representatives captures the class's range:
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Cannabis | Plant preparation | The primary vehicle for phytocannabinoid exposure; effects reflect a mixture of THC, CBD, and minor cannabinoids rather than any single compound |
| Δ-9-THC | Phytocannabinoid (5-carbon chain) | Reference psychoactive compound of the class; CB1 partial agonist |
| Δ-8-Tetrahydrocannabinol | Phytocannabinoid isomer | Positional isomer of Δ-9-THC; broadly similar profile with somewhat lower potency |
| CBD | Phytocannabinoid (non-intoxicating) | Low CB1 affinity; modulates rather than activates the receptor; anxiolytic and anticonvulsant uses |
| THCV | Phytocannabinoid (3-carbon chain) | Short-chain analogue that flips from CB1 antagonist to agonist as exposure rises |
| THCP | Extended-chain phytocannabinoid | Seven-carbon side chain confers substantially higher CB1 binding affinity than Δ-9-THC[3] |
| HHC | Semi-synthetic | Hydrogenated THC; the (9R) epimer is the active CB1 partial agonist[8] |
| CBC | Minor phytocannabinoid | CB2-selective with little CB1 engagement; non-intoxicating |
These members differ widely — some are strongly psychoactive, some are not, and several modulate rather than activate cannabinoid receptors. What unites them is engagement with the same receptor system, and ordinary exposure to the plant or any of its concentrates typically involves several of them at once.
Subjective Effects
Across the class, the experiential trajectory tracks the degree of CB1 activation. Members that do not engage CB1 — chiefly CBD and CBC — do not produce the intoxicating pattern at all, and instead show anxiolytic, anti-inflammatory, or anticonvulsant profiles.[4]
| Exposure | Characteristic effects |
|---|---|
| Low | Relaxation, mild euphoria, a sense of ease, heightened color and sound, altered time perception, and increased appetite, alongside dry mouth and conjunctival redness |
| Moderate–high | Deeper cognitive slowing, impaired short-term memory and reaction time, noticeable motor incoordination, marked tachycardia, and rising likelihood of anxiety |
| High | Intense anxiety or panic, dissociation, paranoia, and — particularly with high-affinity members or concentrates — transient psychotic episodes in vulnerable users[2] |
The same axis — degree of CB1 activation — drives both the sought effects (relaxation, sensory enhancement, appetite) and the unwanted ones (anxiety, paranoia, memory disruption, psychomotor impairment), and the margin between them narrows as exposure rises or as higher-potency members are used.[7]
Safety
Risk profile
The defining acute risks of this class are CB1-driven psychiatric and cardiovascular reactions at higher exposures: panic, paranoia, transient psychosis, and a dose-dependent tachycardia that can become medically significant in those with pre-existing cardiovascular disease.[9] Risk rises with high-potency concentrates and with newer high-affinity homologs whose human safety data is limited.
Tachycardia is the most consistent acute physiological finding across cannabinoid use, develops rapidly after inhalation, and resolves over the following hours. Atrial fibrillation, ventricular arrhythmia, and rare acute coronary events have been temporally associated with cannabis use, particularly in people with established cardiovascular disease.[9]
Acute psychiatric reactions — panic, paranoia, transient psychotic episodes — concentrate in inexperienced users, in those with personal or family history of psychosis, and with high-potency preparations.[2] Cognitive and psychomotor impairment is dose-dependent and can outlast the subjective sense of intoxication; cannabis-impaired driving is associated with substantially elevated crash risk.[2] Combining cannabinoids with alcohol, opioids, or benzodiazepines additively deepens sedation and psychomotor impairment.
Chronic heavy use — predominantly of THC-dominant preparations — can produce cannabinoid hyperemesis syndrome, a paradoxical cycle of recurrent severe vomiting often relieved transiently by hot bathing. It is a recognized emergency presentation, and resolves with cessation of use.[2]
Tolerance & dependence
Repeated CB1 agonist exposure produces tolerance through downregulation and desensitization of CB1 receptors: receptor density falls in CB1-rich regions (prefrontal cortex, hippocampus, striatum, cerebellum), and signaling efficiency drops per remaining receptor.[7] Cross-tolerance is expected among CB1-active members: regular THC users will show reduced response to Δ-8-THC, HHC, and other CB1 agonists in the class. Members that do not engage CB1 — CBD, CBC — do not drive this tolerance.
Dependence is primarily psychological in character but has a physical component, evidenced by a defined withdrawal syndrome. Cannabis use disorder is a recognized DSM-5 diagnosis that affects a substantial minority of regular users, with risk rising on daily use, early-life initiation, and higher-potency products; no pharmacotherapy is currently approved for it.[10]
The cannabis withdrawal syndrome itself is well characterized: irritability and aggression, anxiety and nervousness, sleep disturbance, decreased appetite, restlessness, and depressed mood appear shortly after cessation, peak within the first several days, and largely resolve over the following weeks.[11] Unlike alcohol or benzodiazepine withdrawal, phytocannabinoid withdrawal is uncomfortable but not life-threatening, and clinical supervision is recommended for support rather than for safety.
Recovery
Cannabinoid dependence is treatable. The acute withdrawal phase generally passes over a few weeks, and measurable improvements in working memory, attention, and executive function emerge with sustained abstinence. The established recovery pathways are psychosocial — cognitive behavioural therapy, motivational enhancement, and contingency management. If you or someone you know is struggling with cannabis use, a clinician or substance-use service can structure cessation and support recovery.[10]
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1] ^abcdZou S, Kumar U (2018) Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System — International Journal of Molecular Sciences doi:10.3390/ijms19030833
- [2]
- [3] ^abcCitti C, Linciano P, Russo F, Luongo L, Iannotta M, Maione S, Laganà A, Capriotti AL, Forni F, Vandelli MA, Gigli G, Cannazza G (2019) A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol — Scientific Reports doi:10.1038/s41598-019-56785-1
- [4] ^abcPertwee RG (2007) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin — British Journal of Pharmacology doi:10.1038/sj.bjp.0707442
- [5] ^Udoh, M. and Santiago, M. and Devenish, S. and McGregor, I.S. and Connor, M. (2019) Cannabichromene is a cannabinoid CB2 receptor agonist — British Journal of Pharmacology doi:10.1111/bph.14815
- [6] ^Walsh KB, McKinney AE, Holmes AE (2021) Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses — Frontiers in Pharmacology doi:10.3389/fphar.2021.777804